9
4
3
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T6334 | Ridaforolimus | AP23573,Deforolimus,MK-8669 | mTOR , Autophagy |
Ridaforolimus (AP23573) is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamyc... | |||
T29165 | XC-302 free base | XC 302,Puquitinib,XC-302,XC302 | |
XC-302 is a multi-targeted inhibitor, it induces autophagy of nasopharyngeal cancer cells via inhibiting the PI3K/AKT/mTOR signaling pathway. | |||
T63211 | AKT-IN-10 | ||
AKT-IN-10 is a potent AKT inhibitor that has shown research potential in breast and prostate cancers. Among them is protein kinase B (PKB, also known as AKT), which is central to PI3K/AKT/mTOR signaling in cells and whos... | |||
T79332 | Antiproliferative agent-32 | Apoptosis | |
Antiproliferative agent-32 (Compound 1c) impedes phosphorylation within the PI3K/Akt/mTOR signaling pathway, restrains proliferation of Huh7 and SK-Hep-1 cells, induces apoptosis, and inflicts mitochondrial damage, rende... | |||
T61990 | Topoisomerase I/II inhibitor 3 | ||
Topoisomerase I/II inhibitor 3 (compound 7) is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) . By inhibiting PI3K /Akt/mTOR signaling pathway, Topoisomerase I/II inhibitor 3 can inhibit cell prolif... | |||
T36085 | PKI-179 hydrochloride | ||
PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, resp... | |||
T61476 | Thioridazine | ||
Thioridazine is a chemical compound characterized by its potent anti-psychotic and anti-anxiety activities. As an antagonist of the dopamine receptor D2 family proteins, it exhibits a strong inhibitory effect on the PI3K... | |||
T82971 | ARI-1 | ||
ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor that binds to ROR1's extracellular Frizzled domain, effectively inhibiting aberrant ROR1 expression linked to non-small cell lung cancer (NSCLC)... | |||
T38263 | TBK1/IKKε-IN-4 | TBK1/IKKε-IN-4 | |
TBK1/IKKε-IN-4, a 6-aminopyrazolopyrimidine derivative, serves as a potent, selective inhibitor for TBK1 and IKKε, demonstrating IC50 values of 13 nM and 59 nM, respectively. This compound exhibits significantly reduced ... |
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
TN1405 | Arnicolide D | Akt , Caspase , PI3K , STAT , mTOR | |
Arnicolide D is a sesquiterpene lactone. Arnicolide D isolates from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling path... | |||
T4672 | Brevilin A | Apoptosis , Anti-infection , JAK , STAT , Autophagy | |
Brevilin A is a sesquiterpene lactone isolated from Centipeda minima, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells with anti-tumor activity. Brevilin A is a selective inhibitor of JAK-STAT si... | |||
T2P2806 | Hederacolchiside A1 | Raddeanoside R13 | Apoptosis , ERK , MEK , Akt , PI3K , Parasite , mTOR |
Hederacolchiside A1 (Raddeanoside R13) shows anti-leishmanial activity, it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. Hederacol... | |||
T27305 | Fascaplysin chloride | NSC622398,NSC 622398,Fascaplysin,NSC-622398 | |
Fascaplysin is a cyclin D kinase 4/ cyclin D1 inhibitor (IC50 = 0.35 μM). Fascaplysin induces caspase mediated crosstalk between autophagy and apoptosis through the inhibition of PI3K/AKT/mTOR signaling cascade in human ... |
カタログ番号 | 製品名 | ||
---|---|---|---|
L1300 | PI3K-AKT-mTOR Compound Library | 425 compounds | |
A unique collection of 425 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with PI3K/Akt/mTOR signaling; | |||
L2193 | Anti-Liver Cancer Compound Library | 1816 compounds | |
1816 species of compounds related to liver cancer that can be used in anti-liver cancer drug development and pharmacological studies. | |||
L2195 | Anti-Prostate Cancer Compound Library | 2096 compounds | |
2096 compounds associated with prostate cancer that can be used for high-throughput and high-content screening. |